The Chairperson of the Board of Directors of the Arab Company for Drug Industries and Medical Appliances (ACDIMA), affiliated with the Egyptian Health and Population Ministry, Olfat Ghorab announced that there is a plan to produce 76 high-value cancer medicines.
During an interview with the Egyptian TV on Tuesday, Ghorab added that the plan also aims to produce cancer treatment in the first half of 2023.
She continued that the manufacture of contraceptive drugs will be fully localized, pointing out that producing medicines locally would reduce the import bill, absorb pharmacy and science graduates, and provide medicine on time, at a value that is 50 percent less than its imported counterpart.
Ghorab explained that the targeted local manufacturing will be through a foreign partnership in technology transfer from America and France, with production lines and high capacities in accordance with the standards of manufacturing this type of medicine to ensure the safety of the product.
She stressed that the Egyptian medicine is known for its high quality and efficiency, revealing that 90 percent of the medicines are provided locally at a value of LE 48 billion per month, adding: “all medicines will be manufactured in Egypt by the end of 2024.”
